The stability of epigenetic factor ASXL1 is regulated through ubiquitination and USP7-mediated deubiquitination

Histone H2B monoubiquitination: roles to play in human malignancy

(2014) Alexander J Cole et al.   ENDOCRINE-RELATED CANCER

The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes

(2014) Robert Huether et al.   Nature Communications

Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome

(2014) T-C Chen et al.   Blood Cancer Journal

Regulation of proteolysis by human deubiquitinating enzymes

(2013) Ziad M. Eletr et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice

(2013) J. Wang et al.   BLOOD

Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations

(2013) Daichi Inoue et al.   JOURNAL OF CLINICAL INVESTIGATION

Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo

(2013) Omar Abdel-Wahab et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

(2013) T Haferlach et al.   LEUKEMIA

A common ancestry for BAP1 and Uch37 regulators

(2012) Luis Sanchez-Pulido et al.   BIOINFORMATICS

Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes

(2011) Felicitas Thol et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic and Quantitative Assessment of the Ubiquitin-Modified Proteome

(2011) Woong Kim et al.   MOLECULAR CELL

Ubiquitin-specific proteases 7 and 11 modulate Polycomb regulation of the INK4a tumour suppressor

(2010) Goedele N Maertens et al.   EMBO JOURNAL

Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia

(2009) C. L. Fisher et al.   BLOOD

The deubiquitinylation and localization of PTEN are regulated by a HAUSP–PML network

(2008) Min Sup Song et al.   NATURE